Under the collaboration, Invitae will gain access to Kew's 435-gene tumor profiling NGS panel and proprietary bioinformatics software.
The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.
The companies are accelerating the pace of an existing collaboration with the goal of detecting SMA "2+0" carrier status.
The collaborative study includes testing urine samples from patients who have an increased risk for complicated urinary tract infections.
The firms said that they are integrating CTC isolation and analysis technologies to create a workflow that provides clinical insights to physicians.
FlowMetric said that by combining products, the partners will provide consumers with data security and the ability to govern how their personal information is shared, utilized, and monetized.
The collaboration will use AI to determine if patients can be grouped based on diagnostic test information, potentially leading to quicker and better diagnoses and treatments.
Siemens plans to offer 150 million shares, including 19.6 million shares to cover any overallotment, at between €26 to €31 per share.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
The firms are collaborating to develop a solution that includes Nightingale's nuclear magnetic resonance assay and PerkinElmer's sequencing services.